Attached files

file filename
EX-99.1 - EX-99.1 - Inari Medical, Inc.nari-ex991_6.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 15, 2020

 

INARI MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-39293

45-2902923

( State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer
Identification No.)

 

 

 

 

 

 

 

9 Parker, Suite 100

Irvine, California, 92618

 

 

(Address of principal executive offices)

 

 

(877) 923-4747

(Registrant’s telephone number, include area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, $0.001 par value per share

 

NARI

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 17, 2020, Inari Medical, Inc. (the “Company”) announced the promotion of Andrew Hykes, age 47, to the position of Chief Operating Officer of the Company, effective September 1, 2020.

In connection with Mr. Hyke’s promotion as Chief Operating Officer, on September 15, 2020 the Compensation Committee of the Board of Directors of the Company approved an increase to Mr. Hykes’ annual base salary from $400,000 to $450,000, effective September 1, 2020. In addition, he will remain eligible for an annual bonus, equity awards and other employee benefits in accordance with the Company’s compensation program.  

Mr. Hykes joined the Company as Chief Commercial Officer in September 2017. From November 2012 to January 2017, Mr. Hykes was the Vice President of Commercial Operations of Sequent Medical Inc., a private company focused on catheter-based neurovascular therapies that was acquired by Terumo Corporation in July 2016. Prior to this, Mr. Hykes worked for Medtronic PLC, a public medical device company, from August 2002 to October 2012, where he held several positions including Vice President of Marketing, Vice President of Clinical and Regulatory Affairs and Director of Investor Relations. From 1995 to 2000, Mr. Hykes worked in healthcare banking for ABN AMRO Bank. Mr. Hykes received his B.B.A. from the University of Wisconsin Madison and an M.B.A. from Harvard Business School.

There is no arrangement or understanding between Mr. Hykes and any other persons pursuant to which Mr. Hykes was promoted, there are no family relationships between Mr. Hykes and any of the Company’s directors or executive officers, and there are no related party transactions involving Mr. Hykes that are reportable under Item 404(b) of Regulation S-K.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

 

 

Description

99.1

 

Press release dated September 17, 2020

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

INARI MEDICAL, INC.

 

 

 

 

Date: September 17, 2020

 

By:

/s/ William Hoffman

 

 

 

William Hoffman

 

 

 

President and Chief Executive Officer